The Open Biochemistry Journal · 2014 · 11 citations · 29 references
Life SciencesEndocrinologyPharmacologyMetabolic RegulationMetabolismSignal TransductionCarbohydrate MetabolismDiabetes MellitusDiabetes Mellitus BiochemistryIncretin-based TherapiesInsulin ResistancePancreatic HormonesGlucagon-like Peptide 1 SignalingGlucagon-like PeptidesHepatic Fuel MetabolismIncretin EffectIncretin HormonesIncretin PhysiologyIncretin SignalingMitochondrial Pathways
Glucagon-like peptide-1 (GLP-1), which has been extensively applied for treating type 2 diabetes mellitus (T2DM), is an incretin hormone that regulates glucose homeostasis. GLP-1(28-36)amide, a C-terminal nonapeptide (FIAWLVKGRamide) of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide has long been regarded as a metabolically inactive byproduct, however, recent findings reveal that GLP-1(28-36)amide plays multiple novel roles in ameliorating hepatic metabolism, protecting β cells, improving glucose disposal and inhibiting weight gain. Here, we summarize the latest progress on the effects of GLP-1(28-36)amide with a focus on its roles in regulating the Wnt and mitochondrial-mediated signaling pathways.
29
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Yazhou Li, Tanya Hansotia, Bernardo Yusta et al. · Journal of Biological Chemistry · 2002 · 590 citations · Full text